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A B S T R A C T
We present a case of Cryptococcus neoformans in an immunocompetent middle-aged woman with a
disseminated manifestation of pulmonary cryptoccoma and cryptococcal meningitis resulting in bilateral
blindness. The presentation was complicated by delayed diagnosis resulting in optic neuritis and an
infected percutaneous lumbar drainage with methicillin resistant staphylococcus aureus (MRSA) and a
paradoxical reaction of suspected immune reconstitution inflammatory syndrome (IRIS). We discuss the
pathogen, the clinical manifestations and diagnostic approach (through laboratory and radiology
findings), differential diagnosis, treatment, and proposed pathogenesis of IRIS and C. neoformans in an
immunocompetent patient.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Immunocompromised patients are particularly susceptible to
Cryptococcus infections with Cryptococcus gattii being the predom-
inant type in immunocompetent hosts. [1] The incidence of AIDS-
associated cases in Australia have declined annually and
Cryptococous infection is more common in Aboriginal and Torres
Strait Islander people in rural or semirural locations and in
immunocompetent males [2,3]. Therefore clinical manifestations
of the disease is influenced more strongly by host immune status
than by Cryptococous variety [1]. Cryptococcus neoformans is less
commonly encountered and 10–30% of cryptococcal meningitis
presentations occur in non-human immunodeficiency virus (HIV)
patients [4]. Common treatment of Cryptococcal meningitis
comprises of antifungal therapy and management of increased
intracranial pressure [5]. Success rates are high with this
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and immunocompetent individuals infected with Cryptococcus.
Immunocompetent patients generally present with pulmonary
cryptoccoma [6–9] or meningoencephalitis, whilst immunocom-
promised patients more commonly present with meningoenceph-
alitis [10,11]. Diagnosis if often delayed in immunocompetent
patients given the condition is rare, resulting in a poorer prognosis
[12,13].
Atypical presentations of C. neoformans is rare, nevertheless
requires careful consideration in the clinical setting [14–16].
Regardless of a patients’ immune status, a thorough and systematic
clinical evaluation and prompt management is crucial in order to
prevent the occurrence of sinister complications such as optic
neuritis [17,18]. In the context of symptom relapse, consideration
of paradoxical immune reconstitution inflammatory syndrome
(IRIS) reactions and initiation of early steroid treatment is an
important consideration [19–22]. Here we present the clinical
journey of an immunocompetent patient who presented with
disseminated C. neoformans infection resulting in IRIS and
permanent bilateral vision loss.
Case description
A 41-year-old Caucasian woman presented to a regional tertiary
hospital in August 2018 with an eight week history of intermittent
headaches, dizziness, and visual disturbance. She had initially
presented to her general practitioner that morning who promptlyder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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headaches were localized around the occipital cortex with a
gradual onset and had been worsening over two weeks and were
associated with dizziness, visual blurriness, and morning emesis.
She reported associated unintentional weight loss of 10 kg over a
month. The patient was previously well and her only prescribed
medication was Carbamazepine 400 mg twice a day for epilepsy
diagnosed at the age of 30 with no recent history of seizure relapse.
She had no history of HIV, Tuberculosis, exposure to pigeons, or
any immunosuppressive treatments. She was investigated with
blood and biochemical tests and a brain computed tomography
(CT) scan, which were unremarkable. A provisional diagnosis of
occipital neuralgia was made and 50 mg of oral Pregabalin twice
daily was prescribed and the patient was discharged with a referral
for an outpatient Magnetic Resonance Imaging (MRI) scan of her
brain, and an outpatient neurologist review appointment in a
month.
Three weeks later she re-presented to our center and was re-
admitted with worsening headache and associated nausea and
vomiting, bilateral double vison on lateral gaze, dry cough, and
shortness of breath; along with a diagnosis of bilateral abducens
nerve (CN VI) palsy. An initial chest radiograph showed a right
middle lobe consolidation (Fig. 1) and the patient was treated for
community acquired pneumonia with intravenous (IV) ceftriaxone
1 g and doxycycline 100 mg orally. The patient had an initial
C-reactive protein (CRP) of 46 mg/L. An inpatient MRI scan was
organized to investigate a cause of her persistent headache and her
cranial nerve palsy and a neurological opinion was requested.
The MRI brain scan showed a small meningioma in her right
frontal cortex, with evidence of meningitis and the patient
underwent a lumbar puncture which showed high opening
pressure (> 34 cm H2O), high protein (1100 mg/L), low glucose
(14 mmol/L), high white cell count (220  106/L) with 83 %Fig. 1. Chest Radiograph shows an opacity in the right midzone with an ovoid, well-defin
3.4  2 cm in maximal axial dimensions.mononuclear cells and a positive cryptococcal titer of 1:1024.
Cerebrospinal fluid (CSF) culture showed growth of C. neoformans.
She was commenced on daily IV amphotericin B (AmBisome
liposomal 50 mg), 5 mg/kg and oral 5-fluorocytosine 1500 mg
6 -hly for a duration of six weeks as induction therapy followed by
fluconazole 600 mg daily for eradication. A chest CT scan was taken
which showed possible large cryptoccoma (Fig. 2). This was
confirmed with bronchoscopy and bronchial lavage.
During the admission, the patient required lumbar percutane-
ous drainage due to persistently high intracranial pressure. The
percutaneous drainage site became infected by Methicillin-
resistant Staphylococcus aureus (MRSA) infection although she
was negative for MRSA colonization previously. This was treated as
a hospital acquired infection and required the removal of the drain
for source control and IV vancomycin 1 g twice a day and
rifampicin 300 mg daily, orally for two weeks. The initial
presenting symptoms began to improve and the CSF had evident
cryptococcal clearance by week three following treatment and she
was transferred to the rehabilitation ward on oral Fluconazole
400 mg daily. An external ventricular drain (EVD) was inserted by
the neurosurgical team to control raised intracranial pressure.
However the patient continued to deteriorate clinically with
persistent headaches, nausea and vomiting, and visual impairment
along with ongoing high output EVD; resulting in eventual
insertion of a ventriculoperitoneal (VP) shunt by the neurosurgical
team during the fifth week of admission.
At week seven, she developed a fever (38.2c), worsening
vision, confusion, and a non-localized headache. Her septic screen
was unremarkable and a repeated CSF analysis showed normal
open pressure, with markedly increased protein (4300 mg/L), and
raised white cell count (191 106/L). A repeated MRI brain revealed
gyro hyper-intensity on the fluid-attenuated inversion recovery
(FLAIR) study which was a novel finding (Fig. 3). Despite intensiveed fluid density structure in the superior aspect of the right middle lobe measuring
Fig. 2. CT tomography of chest in axial and coronal view shows middle lobe consolidation of the Right lung, suggestive of cryptoccoma.
Fig. 3. MRI-FLAIR (Fluid-attenuated inversion recovery) study depicting gyro hyper-intensity on the FLAIR study pre-contrast and post-contrast. The post contrast MRI image
depicts meningeal enhancement through gyro hyper-intensity on the FLAIR study.
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every 12 h, her level of consciousness deteriorated. She was
admitted to the intensive care unit (ICU) and required endotracheal
intubation and monitoring for 48 h. Her CSF culture remained
negative. IRIS was strongly suspected at this point, and a high dose
of IV steroids was administered along with oral prednisolone. The
patient remarkably improved within the next week and returned
to the ward for continuation of rehabilitation. However, her vision
remained severely impaired.
The patient had two visual evoked potential tests with no
abnormal results and normal baseline visual examination. During
Ophthalmology review during week ten of admission, bilateral
optic neuropathy was confirmed, and she was declared legally
blind. During her admission the patient tested negative forHepatitis B and HIV repeatedly (eight weeks apart) but had
positive hepatitis C antibodies with evidence of past infection
(IgG), normal immunoglobulin levels (IgG, IgA, IgM) and normal
complement levels.
Search strategy
References for this review were identified through searches of
Ovid MEDLINE (1946 to 7 May 2019); Elsevier SCOPUS (1960 to 13
May 2019; by use of the terms “Cryptococous”, “Immunocompe-
tence”, “Cryptoccoma” and “Cryptococcal meningitis”. Articles
resulting from these searches and relevant references cited in
those articles were reviewed. Articles published in English were
included in the review where the article contained a study
4 R. Kathiresu et al. / IDCases 19 (2020) e00699reporting on a case study of Cryptococcus neoformans in an
immunocompetent host. Articles in other languages were excluded
unless an English translation existed.
Discussion
A case of Cryptococcus neoformans infection in an immuno-
competent woman with a disseminated manifestation, including
spread cryptoccoma in her lungs, and Cryptococcal meningitis is
presented. The patient initially presented with the symptom
constellation of headache, nausea, fatigue and altered mental
status which mimics many other conditions. The treatment was
complicated by optic neuritis, an infected percutaneous lumbar
drainage with methicillin resistant staphylococcus aureus
(MRSA), and a suspected paradoxical reaction of IRIS. Whilst
cranial nerve palsies and ophthalmoplegia are well documented
complications of this disease, bilateral complete ophthalmoplegia
is a rare presentation [23]. Our patient relapsed whilst on
antifungal treatment despite an undetectable cryptococcal
antigen on CSF analysis and continued to deteriorate despite
antifungal therapy [24].
Subsequently, administration of corticosteroid treatment for
suspected IRIS resulted in significant improvement in overall
symptoms, but the optic neuritis symptoms persisted with poor
visual acuity ending in permanent vision loss. This was a devasting
outcome for the patient and may have been avoided with early
diagnosis. The outcome was considered likely as a result of chronic
raised intracranial pressure and the end result of cryptococcal
meningitis. Reduced visual acuity is likely secondary to bilateral
optic neuropathy or ischemia secondary to inflammation and
cortical atrophy as a result of meningitis. However, this case report
supports adjunctive corticosteroid therapy in the management of
suspected cases of IRIS following C. neoformans meningitis treated
with first-line antifungal treatment leading to initial overall
improvement.
Cryptococcus are basidiomycetes that are encapsulated yeasts.
C. neoformans and C. gattii are the chief pathogens in humans, and
inhalation is the usual route of primary infection [25].Table 1


















































Male 23 Headache, weight loss, an
multiple syncopal episode
Legend: The table contains data from previous case-reports reporting on Cryptococcus C. neoformans was originally discovered by Sanfelice in 1894 [4],
and is a ubiquitous pathogen found in most temperate regions of
the world commonly found in decaying organic matter and in
many soil types, particularly that which has been enriched by
animal and bird droppings [26]. In a retrospective study, 29 cases of
cryptococcal infections were diagnosed in our local hospital region
between 1997 and 2015 [3]. The reported overall mortality rate was
10.3 %, with an attributable mortality rate of 6.9 %. Forty-five per
cent of patients with central nervous system (CNS) involvement
developed long-term neurological deficits and this was attributed
to delayed diagnosis as both time from onset of symptoms to
diagnosis (median of 45.5 days versus 18.5 days, respectively) and
time from presentation to diagnosis (median 14.5 days versus 7
days, respectively) differed compared to cases without CNS
involvement [3]. Our patient was diagnosed well outside both
median timeframes hence delayed diagnosis of C. neoformans
continues to be a major problem not only in our region but
worldwide [10,15].
Interestingly, raised intracranial pressure and female gender are
significantly associated with poor neurological outcomes (both
relevant to our patient) [3]. A more recent retrospective multi-
centre analysis of immunocompetent patients diagnosed and
treated for cryptococcal meningitis in Australia indicated 67 of the
143 cases (46.8 %) of cryptococcosis occurred in immunocompe-
tent patients [2]. The relative risk of meningitis with a serum
cryptococcal antigen >1:64 was 1.8 (95 % CI 1.15–2.82) [3]. This
suggests that C. neoformans infections are relatively common in
immunocompetent individuals and therefore needs to be consid-
ered as a differential diagnosis in the setting of non-specific
neurological symptoms. A unique aspect of the case presented was
disseminated disease in an immunocompetent patient [13]. We did
not find any evidence of an immunodeficiency despite extensive
investigation for acquired immunodeficiency, but an underlying
sub-clinical immunodeficiency was possible. This is contradictory
to the typical presentations of C. neoformans in immunocompetent
patients [6–11].
Consideration of a wide range of differential diagnoses in







4 weeks 1:1024 Liposomal amphotericin B 180 mg intravenous
once daily for 2 weeks; Flucytosine 1500 mg
every 6 hours orally for 2 weeks and
Fluconazole orally for 1 year after induction
therapy
6 weeks 1:100 Amphotericin B at a dose of 300 mg/day for 70
days, flucytosine 1500 mg four times a day for
40 days and at day 40 she started fluconazole
with maintainance (400 mg/day).
2 months 1:4096 Intravenous liposomal amphotericin (l-AMB)
3 mg/kg daily and 5-FC 25 mg/kg 6-hourly
2 weeks – –
d 1–2
weeks
Negative Intravenous liposomal amphotericin B (5 mg/kg
per day) and flucytosine (25 mg/kg four times a
month.
6 weeks 1:2,04 Liposomal amphotericin B (L-AMB; 5 mg/kg per
day) and flucytosine (25 mg/kg four times a day
d
s
8 weeks 1:1024 Amphotericin B, flucytosine and fluconazole;
unreported doses.
neoformans infection in immunocompetent individuals.
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symptoms [14]. The differential diagnosis for cryptococcal infec-
tion includes; Granulomatous diseases, cavernous sinus thrombo-
sis, internuclear ophthalmoplegia or demyelinating lesions and
Hepatitis B virus related vasculitis [15]. If suspecting a Cryptococ-
cus presentation, screening for pulmonary, skin and neurological
manifestations is essential [26,27]. An in-depth ocular examina-
tion is of importance to detect early signs of intracranial
hypertension and ophthalmoplegia [17,18]. A brain CT-scan is
not reliable in the case of c. neoformans encephalitis, nor raised
intracranial hypertension; however, MRI and lumbar puncture are
imperative as was seen in the case study. Upon suspicion of
meningoencephalitis, investigation of Cryptococcus antigen in
lumbar puncture is advised, regardless of the immune status of the
patient [28].
A summary of previously reported case reports from a search of
the literature on C. neoformans is provided below (Table 1). In
immunocompetent patients, presentations predominate with
isolated pulmonary Cryptococcus. A third of the patients were
diagnosed incidentally on chest x-ray. Initial presenting symptoms
included dyspnoea, dry cough and haemoptysis. Guidelines
stipulate that confirmed pulmonary cryptoccoma should be
treated with fluconazole 200 mg for 6–12 months regardless of
the patients’ immune status [29,30]. In asymptomatic pulmonary
infection or post-surgical excision, treatment is still recom-
mended.22 This is however under the condition that they are to
be strictly monitored clinically and be within stipulated laboratory
guidelines [21,24]. The Updated Clinical Practice Guidelines for the
Management of Cryptococcal Disease by the Infectious Diseases
Society of America [31] stipulates that induction therapy for
meningoencephalitis using fungicidal regimens, such as a polyene
and flucytosine, followed by suppressive regimens using flucona-
zole, early recognition and treatment of increased intracranial
pressure and IRIS; and the use of lipid formulations of amphoteri-
cin B regimens in patients with renal impairment are important
considerations [5,32,33]. There is however much controversy on
duration and type of treatment [21].
Our patient had persistent raised intracranial pressure despite
the initial EVD shunt, complicated with optic neuritis [18,34]. This
is known to lead to neurological sequalae or death within a period
of 12 months in C. gattii meningoencephalitis but is not reported in
in C. neoformans [21]. High CSF pressure is conventionally
controlled with serial lumbar punctures, or otherwise by
neurosurgical intervention via EVD or VP shunts [34]. Our patient
required neurosurgical intervention, and as an early neurological
opinion was sought regarding recommendation for early interven-
tion, neurosurgical intervention (within 1–2 weeks) was in order
as frequent lumbar punctures did not adequately control CSF
pressure [34]. The patient suffered neurological sequelae in the
form of visual loss likely secondary to persistently high CSF
pressures and an inflammatory optic neuritis leading to optic
atrophy [18].
As mentioned the patient was managed with a 6-week IV
induction treatment of liposomal amphotericin B and flucytosine
and was diagnosed with IRIS at 7 weeks post commencement of
anti-fungal treatment [5,24,35]. During antifungal therapy of
cryptococcal meningitis, clinical deterioration may occur despite
evidence of mycological response. This paradoxical heightened
immune response is increasingly recognized in immunocompetent
hosts [33,36]. IRIS is a recognised complication of C. neoformans
treatment in immunocompromised patients and not very common
in immune competent patients, typically manifesting as neurolog-
ical symptoms of headache, fevers and meningism [21]. Brain
imaging may identify new lesions or increased leptomeningeal
enhancement, and lumbar puncture typically demonstrates a
culture-negative pleocytosis as was the case in our patient. Thepathogenesis of IRIS has not been definitively defined. IRIS is
characterized by an increase in immune regulatory natural killer
(NK) cells and IFN-g-dependent factors such as monocyte
attractant CXC motif chemokine (MCP-1) [37]. Such an inflamma-
tory state is particularly problematic in cryptococcal meningitis, as
the closed compartment of the brain within the skull allows little
expansion with inflammation or cerebral oedema [33,34]. There is
much controversy regarding the management of severe cases of
cryptococcal meningitis as response to steroids are unexpected
and host-specific immune characterizations are poorly under-
stood.
Specific risk factors for the development of cryptococcal IRIS in
immunocompromised people include a shorter duration between
cryptococcal diagnosis and antiretroviral drug initiation, low CD4
counts (<100 cells/ml), higher baseline plasma HIV RNA levels;
and higher CSF cryptococcal antigen titres or CSF opening
pressures, WBC count, and glucose levels. Unlike many other
forms of IRIS, which produce less dramatic consequences,
Cryptococous associated IRIS is exceptional for its substantial
morbidity and mortality and cases are seldom reported in
immunocompetent individuals [37].
For major manifestations such as raised ICP, treatment
guidelines recommend corticosteroid therapy [31]. The early
initiation of steroids is proposed in order to minimise the
neurological complications and permanent sequelae. 31 Mani-
festations of IRIS include worsening, or relapse, of clinical
symptoms with or without radiological findings as described
earlier [22]. The duration of time from CSF culture clearance and
onset of IRIS can be up to three months due to often negative
antigen titres and evidence of bacterial meningitis, despite
lumbar percutaneous drainage of infection [21]. Here we
demonstrate how IRIS was successfully managed with high-dose
intravenous corticosteroids, followed by an oral course that was
tapered over 6 months [31].
Conclusion
This case study highlights the importance of early diagnosis
and the need to limit raised intracranial pressure to minimize
long-term neurological deficits in immunocompetent patients
with C. neoformans [10,21,33]. The literature related to manage-
ment has been reviewed and there appears to be limited case
reports on the manifestation of IRIS in immunocompetent
individuals with C. neoformans [31]. Atypical presentations of
C. neoformans are rare, nevertheless require careful consideration
in the clinical setting. Regardless of immune status, a thorough
clinical examination followed by early diagnosis and management
is crucial in order to prevent the occurrence of sinister
complications such as optic neuritis from raised intracranial
pressure.
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